Abstract 1114P
Background
Large cell neuroendocrine carcinoma (LCNEC) and small cell carcinoma (SCLC) are both classified as pure and combined subtypes. Due to the low incidence and difficult diagnosis of combined LCNEC (C-LCNEC) and combined SCLC(C-SCLC), no studies have been conducted to compare their clinical features and prognosis.
Methods
We retrospectively analyzed 192 patients who underwent pulmonary surgery and were pathologically diagnosed as C-LCNEC and C-SCLC. We compared the clinical features, driven gene status, and prognosis between the two groups. Univariate and multivariate Cox regression analysis were applied to determine the factors affecting disease-free survival (DFS) and overall survival (OS).
Results
A total of 116 patients with C-LCNEC and 76 patients with C-SCLC were included in the analysis. There were significant differences in smoking history, tumor location, pT stage, pN stage, pTNM stage, VPI and combined components between C-LCNEC and C-SCLC(P＜0.05). The incidence of EGFR mutations in C-LCNEC patients was higher than that in C-SCLC patients (25.7% vs. 5%, P=0.004). We found that tumor size, pN stage, CEA and adjuvant chemotherapy were independently prognostic factors for DFS and OS in C-LCNEC(P＜0.05). NSE, pT stage, pN stage, VPI and adjuvant chemotherapy were independently predictive factors of DFS and OS for C-SCLC(P＜0.05). After adjusting the confounders between the two groups using the PSM method, C-LCNEC patients had a more favorable DFS (P=0.032) and OS (P=0.019) than C-SCLC patients.
Conclusions
There were several significant differences in clinicopathological features and prognosis between C-LCNEC and C-SCLC. Patients with C-LCNEC had better DFS and OS.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.